PNC Financial Services Group
CARM

PNC Financial Services Group’s Carisma Therapeutics CARM Stock Holding History

PNC Financial Services Group’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20
Closed -$244 – 4696
2022
Q4 		$244 Buy
+20
New +$210 ﹤0.01% 4617
2021
Q4 		– Sell
-20
Closed – – 4453
2021
Q3 		$0 Buy
+20
New +$960 ﹤0.01% 4305
2020
Q1 		– Sell
-1
Closed – – 3906
2019
Q4 		$0 Hold
1
– – ﹤0.01% 3993
2019
Q3 		$0 Hold
1
– – ﹤0.01% 3993
2019
Q2 		$0 Hold
1
– – ﹤0.01% 4021
2019
Q1 		$0 Hold
1
– – ﹤0.01% 4033
2018
Q4 		$0 Hold
1
– – ﹤0.01% 4048
2018
Q3 		$0 Buy
+1
New +$39 ﹤0.01% 4119

Other funds holding CARM

TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
Deuterium Capital Management Clearwater, Florida $86M AUM 87.31% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PNC Financial Services Group's CARM Position: Q1 2023 in Review

PNC Financial Services Group sold out of Carisma Therapeutics (CARM) in Q1 2023, closing a stake of 20 shares — an estimated $244 sold.

PNC Financial Services Group first reported a position in CARM in Q3 2018 and held it in 8 quarters. The position peaked at $244 in Q4 2022. 37 funds tracked by Wall St. Rank hold CARM as of Q1 2023.

  • PNC Financial Services Group reported no remaining Carisma Therapeutics position as of Q1 2023 after selling out during the quarter.
  • PNC Financial Services Group sold 20 Carisma Therapeutics shares in Q1 2023, an estimated $244.
  • PNC Financial Services Group first reported a position in Carisma Therapeutics in Q3 2018 and held it in 8 quarters.
  • PNC Financial Services Group's Carisma Therapeutics position peaked at $244 in Q4 2022.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2023.

Based on PNC Financial Services Group's 13F filing for Q1 2023, filed 15 May 2023.